• Biotin-XX Tyramide Reagent in Spatial Proteomics

  2026-08-25

  Biotin-XX Tyramide Reagent combines HRP-driven amplification with membrane exclusion for selective cell-surface detection in tissue sections. This guide translates its chemistry into practical IHC, ISH, multiplex imaging, and proximity-proteomics workflows, with starting parameters and troubleshooting advice.

• Nystatin (Fungicidin): Mechanism & Benchmarks

  2026-08-25

  Nystatin, also called Fungicidin, is an ergosterol-binding polyene antifungal used in Candida and Aspergillus research. Product-dossier benchmarks include species-dependent Candida inhibition, reduced epithelial adhesion, and protective activity from liposomal Nystatin in neutropenic mice.

• Neuromedin S (rat): Protocol and QC Guide

  2026-08-24

  Neuromedin S (rat) provides a defined endogenous peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling in rat-relevant systems. It supports research workflows involving energy homeostasis regulation and stress response research, but the dossier does not establish potency, therapeutic suitability, diagnostic use, or cross-species performance.

• GW4064: FXR Signaling in Fibrosis Assays

  2026-08-24

  GW4064 is a non-steroidal FXR agonist that connects receptor pharmacology with lipid metabolism and toxicant-associated fibrosis research. This article explains how to design more informative FXR assays by integrating pathway, ferroptosis, and collagen readouts.

• Macrophage EP4 Loss in Atherosclerosis

  2026-08-23

  A 2025 Cells study identifies macrophage EP4 as a protective regulator of atherosclerosis, linking its deficiency to increased CD36 expression, foam-cell formation, and M1 polarization. The work combines a myeloid EP4 knockout model, oxLDL-stimulated macrophages, transcriptomics, proteomics, Western blotting, and qPCR to connect an in vivo plaque phenotype with a candidate molecular mechanism.

• Luminescent ATP Detection Assay Kit in NSCLC

  2026-08-22

  Use a firefly luciferase ATP assay to connect pyruvate carboxylase activity with energy status, ferroptosis susceptibility, and tumor progression in NSCLC models. The workflow combines rapid lysis, broad 1 nM–10 μM linearity, and downstream-compatible sample handling for cellular and tissue studies.

• Palmitic acid: Protocol Parameters and QC

  2026-08-22

  Palmitic acid (SKU N2456), also called hexadecanoic acid, provides a defined saturated long-chain fatty acid for lipid metabolism, signaling, and metabolic disorder research. It is intended for solvent-based preparation and prompt use, not aqueous dissolution or long-term storage as a solution.

• Acetylcholine Chloride in Gut-Brain Assays

  2026-08-21

  Acetylcholine Chloride provides a defined cholinergic comparator for testing how microbial signals influence vagal, intestinal, and neuronal function. This practical guide connects the Bacteroides fragilis antiseizure study with reproducible formulation, concentration-response, ex vivo, and troubleshooting workflows.

• GANT61: A GLI Inhibitor for Assay Design

  2026-08-20

  GANT61 is a GLI inhibitor for dissecting distal Hedgehog signaling in cancer models. This article presents an assay-centered framework for connecting GLI2 activity with tumor-cell phenotypes, WNT and prostaglandin signals, and immune suppression without overinterpreting pathway-level results.

• Ciclesonide: From Prodrug Activation to Assay Design

  2026-08-20

  Ciclesonide research depends on separating prodrug activation, glucocorticoid receptor binding, and downstream inflammatory outcomes. This article presents an assay-centered framework and clarifies what ERAD-hijacking research does—and does not—mean for respiratory models.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-08-19

  AZD8055 is a selective ATP-competitive mTOR inhibitor for dissecting mTORC1 and mTORC2 signaling in biochemical, cellular, and selected preclinical models. It is best suited to mechanistic research rather than clinical efficacy assessment, and its poor water and ethanol solubility requires disciplined DMSO-based handling.

• What AKT Inhibitor Pharmacology Reveals

  2026-08-19

  Kostaras and colleagues systematically compared ATP-competitive and allosteric AKT inhibitors using biochemical, cellular, structural, and phosphoproteomic approaches. Their findings show that inhibitor class, AKT isoform, mutation status, and non-catalytic signaling can strongly shape drug activity, offering a framework for interpreting context-specific responses and rational combinations.

• Azathramycin A: From Degradant to TB Assay Tool

  2026-08-18

  Azathramycin A is a macrolide antibiotic that can serve as both a mechanistic probe and an analytical control in tuberculosis research. This guide connects ribosome-focused assay design with compound identity, degradation, and interpretation decisions for more reproducible Mycobacterium tuberculosis studies.

• Homoharringtonine: From Ribosome to Assay Design

  2026-08-18

  Homoharringtonine is a cytotoxic alkaloid whose ribosome-directed activity connects leukemia research with SARS-CoV-2 antiviral research. This evidence-centered guide explains how to distinguish translational inhibition, cytotoxicity, and antiviral effects when designing robust assays.

• BFH772 (VEGFR2 inhibitor): Workflow Guide

  2026-08-17

  BFH772 is a selective small-molecule VEGFR2 inhibitor for experiments that require controlled modulation of VEGFR2-driven angiogenesis and tumor-model signaling. Its organic-solvent solubility and water insolubility make it unsuitable for workflows requiring aqueous formulation or broad-spectrum kinase inhibition without additional formulation and selectivity controls.

7785 records 1/519 page Next 12345 下5页 Last page